Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.01.2021 | Case report

Antineoplastics

Lack of efficacy in T-cell/histiocyte-rich large B-cell lymphoma: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yaman S, et al. ABCL-037: One Year Remission with Allogeneic Stem Cell Transplantation After Achieving Complete Response by Polatuzumab Vedotin for the Treatment of Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 20 (Suppl. 1): S261 abstr. ABCL-037, Sep 2020. Available from: URL: http://doi.org/10.1016/S2152-2650%2820%2930864-8 [abstract] Yaman S, et al. ABCL-037: One Year Remission with Allogeneic Stem Cell Transplantation After Achieving Complete Response by Polatuzumab Vedotin for the Treatment of Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 20 (Suppl. 1): S261 abstr. ABCL-037, Sep 2020. Available from: URL: http://​doi.​org/​10.​1016/​S2152-2650%2820%2930864-8 [abstract]
Metadaten
Titel
Antineoplastics
Lack of efficacy in T-cell/histiocyte-rich large B-cell lymphoma: case report
Publikationsdatum
01.01.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-87903-3

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Morphine

Case report

Etoposide